Reference Summary: Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, reports updates from the first-in-human Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses the results of a ...
A Phase I Dose Escalation 10902 -
Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, reports updates from the first-in-human Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses the results of a ... James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of
Important details found
- Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, reports updates from the first-in-human
- Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses the results of a ...
- James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of
- Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, comments on results from
- Scott Tagawa, FACP, MD, MS, Weill Cornell Medicine, New York, NY, provides an overview of
Why this topic is useful
The goal of this page is to make A Phase I Dose Escalation 10902 easier to scan, compare, and understand before opening related resources.
Frequently Asked Questions
What should readers check next?
Readers should check related pages, official references, or updated sources when details matter.
Why are related topics included?
Related topics help readers compare nearby references and understand the broader subject.
What is this page about?
This page summarizes A Phase I Dose Escalation 10902 and connects it with related entries, references, and supporting context.
